03/28/23 4:25 PMNasdaq : CVAC CureVac Announces Voting Results of Extraordinary General MeetingCureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the voting results of the Company'sRHEA-AIneutral
02/10/23 4:20 PMNasdaq : CVAC offeringCureVac Announces Closing of $250 million Follow-on Public Offering of Common SharesCureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today the closing of its follow-on publicRHEA-AIneutral
02/07/23 2:20 AMNasdaq : CVAC offeringCureVac Announces Proposed Public Offering of Common SharesCureVac N.V. (NASDAQ:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today that it intends to offer $200 million of itsRHEA-AIneutral
02/01/23 7:15 AMNasdaq : CVAC CureVac Welcomes Myriam Mendila as New Chief Development OfficerCureVac N.V. (Nasdaq:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based onRHEA-AIneutral
01/31/23 9:35 AMNasdaq : CVAC CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis(R)RHEA-AIvery positive
01/30/23 8:30 AMNasdaq : CVAC covid-19CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development ProgramsContinued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants in adults age ≥65 Flu: monovalentRHEA-AIneutral
01/09/23 7:15 AMNasdaq : CVAC managementCureVac Appoints Alexander Zehnder as CEO From April 1, 2023CureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical companyRHEA-AIvery positive
01/06/23 7:15 AMNasdaq : CVAC covid-19CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development ProgramsPromising COVID-19 and flu modified mRNA vaccine candidates identified based on positive preliminary data from ongoing Phase 1 studies All candidates use CureVac's advanced second-generation mRNA backbone optimized to achieve improved mRNA translation and strong immune responses at low doses TheRHEA-AIneutral
12/14/22 4:25 PMNasdaq : CVAC CureVac Members of Management Sell Shares to Cover Tax Obligations from Long Term Incentive ProgramCureVac N.V. (NASDAQ:CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Chief Executive Officer Franz-Werner Haas, ChiefRHEA-AIneutral
11/16/22 7:30 AMNasdaq : CVAC earningsCureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business UpdateDelivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 Strengthening oncology position based on preparations for new clinicalRHEA-AIpositive